Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy
Table 4
Clinical pathological data of the gastric cancer patients whose tumor size is larger than 5 cm.
Clinical pathological data
Without postoperative chemotherapy group ( cases)
With postoperative chemotherapy group ( cases)
value
Cases
%
Cases
%
Age (years)
Median
58
62
Range
23–79
41–83
Sex
Male
20
60.6
58
65.9
0.368
Female
13
39.4
30
34.1
Tumor location
Gastric cardia
20
60.6
55
62.5
0.639
Middle
5
15.2
9
10.2
Antrum
4
12.1
17
19.3
Total stomach
4
12.1
7
8.0
CEA level
<5 μg/ml
27
81.8
66
75.0
0.296
≥5 μg/ml
6
18.2
22
25.0
Borrmann type
I
1
3.0
1
1.1
0.819
II
12
36.4
38
43.2
III
19
57.6
46
52.3
IV
1
3.0
3
3.4
Histological grade
High differentiation
0
0.0
0
0
0.077
Median differentiation
8
24.2
38
43.2
Low differentiation
21
63.6
36
40.9
Poor differentiation
4
12.1
14
15.9
T staging
T3
25
75.8
72
81.8
0.307
T4a
8
24.2
16
18.2
LN harvested
15–29
32
97.0
74
84.1
0.045
≥30
1
3.0
14
15.9
Poorly differentiated cells: signet ring cell carcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, etc. The T and N staging for this group of patients is according to the AJCC 7th TNM staging system for gastric cancer.
